35.19MMarket Cap-1824P/E (TTM)
1.050High0.850Low7.38MVolume1.040Open1.040Pre Close8.76MTurnover30.14%Turnover RatioLossP/E (Static)33.84MShares3.07052wk High-5.98P/B25.47MFloat Cap0.80852wk Low--Dividend TTM24.49MShs Float7.000Historical High--Div YieldTTM19.23%Amplitude0.808Historical Low1.186Avg Price1Lot Size
OKYO Pharma Stock Forum
OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company dedicated to developing innovative ocular therapies, has recently announced the grant of a significant European patent. This patent, titled “Compositions Comprising Chemerin Analogs and Methods of Use,” covers the company's novel OK-101 chemerin analogs. Th...
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
OKYO Pharma is set to begin a Phase 2 clinical trial of OK-101 for treating neuropathic corneal pain (NCP) in Q3 2024. This is the first instance of an FDA IND clearance for a drug targeting NCP, a significant unmet medical need. OK-101 has shown statistically significant pain relief in previous trials for dry eye disease and preclinical models of NCP. The 12-week, placebo-controlled trial will be led ...
Dry Eye Disease (DED) is a prevalent condition affecting millions globally, characterized by discomfort, visual disturbance, and potential damage to the ocular surface. Despite the availability of various treatments, many patients continue to seek more effective solutions. In a significant development, OKYO Pharma has announced that its drug, OK-101, has achie...
No comment yet